1/8/2026

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Aftab

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Triamcinolon – för hud och slemhinnor

Triamcinolon – för hud och slemhinnor

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Dhar S, Seth J, Parikh D. Systemic side-effects of topical corticosteroids. Indian J Dermatol. 2014;59(5):460-4.

  2. Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev. 2015;10:CD007346.

  3. Carmichael SL, Shaw GM, Ma C, Werler MM, Rasmussen SA, Lammer EJ et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol. 2007;197(6):585e1-7; discussion 683-4, e1-7.

  4. Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011;183(7):796-804.

  5. Edwards MJ, Agho K, Attia J, Diaz P, Hayes T, Illingworth A et al. Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy. Am J Med Genet 2003;120A:459-63.

  6. Mygind H, Thulstrup AM, Pedersen L, Larsen H. Risk of intrauterine growth retardation, malformations and other birth outcomes in children after topical use of corticosteroid in pregnancy. Acta Obstet Gynecol Scand 2002;81:234-9.

  7. Skuladottir H, Wilcox AJ, Ma C, Lammer EJ, Rasmussen SA, Werler MM et al. Corticosteroid use and risk of orofacial clefts. Birth Defects Res A Clin Mol Teratol. 2014;100(6):499-506.

  8. Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology 1997;56:335-40.

  9. APL. Triamcinolon APL 0,1 % Munhålegel Produktmonografi. AIDA APL [www]. [updated 2016-03-15, cited 2025-12-16].

  10. Läkemedelsverket. Pevisone Produktresumé. Läkemedelsverket [www]. [updated 2023-05-26, cited 2025-12-16].

  11. Ramadas AA, Jose R, Arathy SL, Kurup S, Chandy ML, Kumar SP. Systemic absorption of 01% triamcinolone acetonide as topical application in management of oral lichen planus. Indian J Dent Res. 2016;27(3):230-5.

  12. Katz VL, Thorp JM, Bowes WA. Severe symmetric intrauterine growth retardation associated with the topical use of triamcinolone. Am J Obstet Gynecol. 1990;162(2):396-7.

  1. Dhar S, Seth J, Parikh D. Systemic side-effects of topical corticosteroids. Indian J Dermatol. 2014;59(5):460-4.
  2. Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev. 2015;10:CD007346.
  3. Carmichael SL, Shaw GM, Ma C, Werler MM, Rasmussen SA, Lammer EJ et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol. 2007;197(6):585e1-7; discussion 683-4, e1-7.
  4. Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011;183(7):796-804.
  5. Edwards MJ, Agho K, Attia J, Diaz P, Hayes T, Illingworth A et al. Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy. Am J Med Genet 2003;120A:459-63.
  6. Mygind H, Thulstrup AM, Pedersen L, Larsen H. Risk of intrauterine growth retardation, malformations and other birth outcomes in children after topical use of corticosteroid in pregnancy. Acta Obstet Gynecol Scand 2002;81:234-9.
  7. Skuladottir H, Wilcox AJ, Ma C, Lammer EJ, Rasmussen SA, Werler MM et al. Corticosteroid use and risk of orofacial clefts. Birth Defects Res A Clin Mol Teratol. 2014;100(6):499-506.
  8. Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology 1997;56:335-40.
  9. APL. Triamcinolon APL 0,1 % Munhålegel Produktmonografi. AIDA APL [www]. [updated 2016-03-15, cited 2025-12-16].
  10. Läkemedelsverket. Pevisone Produktresumé. Läkemedelsverket [www]. [updated 2023-05-26, cited 2025-12-16].
  11. Ramadas AA, Jose R, Arathy SL, Kurup S, Chandy ML, Kumar SP. Systemic absorption of 01% triamcinolone acetonide as topical application in management of oral lichen planus. Indian J Dent Res. 2016;27(3):230-5.
  12. Katz VL, Thorp JM, Bowes WA. Severe symmetric intrauterine growth retardation associated with the topical use of triamcinolone. Am J Obstet Gynecol. 1990;162(2):396-7.